This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. 

To learn more about the topics in this episode: 
Biotechs end year 'trading for nothing' as investors mull 'what is IPO-able today?'
Fierce Biotech Layoff Tracker 2023
Editor's Corner—When ASCO dueled with the world's biggest pop star, Swift Biotech was ready for it
Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s

This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/capitulation-has-happened-investors-tepid-about-2024-after-year-ropes" data-cke-saved-href="https://www.fiercebiotech.com/biotech/capitulation-has-happened-investors-tepid-about-2024-after-year-ropes">Biotechs end year 'trading for nothing' as investors mull 'what is IPO-able today?'</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023" data-cke-saved-href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2023">Fierce Biotech Layoff Tracker 2023</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/asco23-buzz-being-back-and-glitter-lots-glitter" data-cke-saved-href="https://www.fiercebiotech.com/biotech/asco23-buzz-being-back-and-glitter-lots-glitter">Editor's Corner—When ASCO dueled with the world's biggest pop star, Swift Biotech was ready for it</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/down-syndrome-and-alzheimers-pharma-clinical-trials-safety-lecanemab" data-cke-saved-href="https://www.fiercebiotech.com/biotech/down-syndrome-and-alzheimers-pharma-clinical-trials-safety-lecanemab">Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement